A recombinant monoclonal antibody against human epidermal growth factor receptor (EGFR) with potential antineoplastic activity. Upon administration, anti-EGFR monoclonal antibody SCT200 targets EGFR, prevents the activation and subsequent dimerization of this receptor and inhibits both EGFR-mediated signal transduction and cellular proliferation of EGFR-expressing tumor cells. In addition, SCT200 may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against EGFR-expressing tumor cells. EGFR, a member of the epidermal growth factor receptor family, is overexpressed on the cell surfaces of various solid tumors.